Johnson & Johnson said worldwide sales for the Q3 quarter of 2026 were $25.4 billion, a total increase of 5.9%, with operational growth of 6.0%. The company also cited the impact of biosimilar competition on STELARA sales decline as approximately 4.2% of worldwide operational sales.

10-QQuarterly reportFiled Oct 21, 2026Period of report Sep 27, 2026Summary published (UTC) Oct 21, 2026

Key points

AI summary

Johnson & Johnson said worldwide sales for the Q3 quarter of 2026 were $25.4 billion, a total increase of 5.9%, with operational growth of 6.0%. The company also cited the impact of biosimilar competition on STELARA sales decline as approximately 4.2% of worldwide operational sales.
The company said earnings before provision for taxes on income for the fiscal 2026 Q3 were $34.0 million, or 0.1% of sales, compared with $7.5 billion, or 31.2%, a year earlier. The period includes a charge of approximately $5.5 billion related to the proposed talc ovarian litigation resolution and $1.0 billion of acquired in-process research and development expense related to the acquisition of Firefly Bio, Inc.
The company said Innovative Medicine segment sales for the fiscal 2026 Q3 rose to $16.8 billion, an increase of 7.7%, while MedTech segment sales rose to $8.6 billion, an increase of 2.5%.
The company said that as of September 27, 2026, it had cash, cash equivalents and marketable securities of approximately $17.2 billion, and notes and long-term debt of approximately $44.6 billion, resulting in net debt of $27.4 billion. The company cited the remaining talc-related payments of approximately $9.0 billion as a use of funds.

Summary

AI-written

Analysis scope · Management's discussion (MD&A)We analyzed excerpts of the Management's Discussion and Analysis (MD&A) section (with omissions). Other sections of the report, such as the notes to the financial statements and risk factors, were not reviewed.

Johnson & Johnson fiscal 2026 Q3 sales $25.4 billion

Johnson & Johnson said worldwide sales for the Q3 quarter of 2026 were $25.4 billion, a total increase of 5.9%, with operational growth of 6.0%. The company also cited the impact of biosimilar competition on STELARA sales decline as approximately 4.2% of worldwide operational sales.

Source · Based on the MD&A text of the filing

Johnson & Johnson Q3 pretax earnings $34.0 million, talc settlement charge $5.5 billion

The company said earnings before provision for taxes on income for the fiscal 2026 Q3 were $34.0 million, or 0.1% of sales, compared with $7.5 billion, or 31.2%, a year earlier. The period includes a charge of approximately $5.5 billion related to the proposed talc ovarian litigation resolution and $1.0 billion of acquired in-process research and development expense related to the acquisition of Firefly Bio, Inc.

Source · Based on the MD&A text of the filing

Segment sales for Q3: Innovative Medicine $16.8 billion, MedTech $8.6 billion

The company said Innovative Medicine segment sales for the fiscal 2026 Q3 rose to $16.8 billion, an increase of 7.7%, while MedTech segment sales rose to $8.6 billion, an increase of 2.5%.

Source · Based on the MD&A text of the filing

Net debt $27.4 billion and remaining talc-related payments of about $9.0 billion

The company said that as of September 27, 2026, it had cash, cash equivalents and marketable securities of approximately $17.2 billion, and notes and long-term debt of approximately $44.6 billion, resulting in net debt of $27.4 billion. The company cited the remaining talc-related payments of approximately $9.0 billion as a use of funds.

Source · Based on the MD&A text of the filing

Structured SEC financial data for this filing is not available yet. Please check the figures in the SEC filing.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.

View the original filing on SEC EDGAR ↗

Unauthorized scraping, data storage and database creation prohibited

Without prior written consent, you must not crawl or scrape data compiled and organized by Chickstock or its analysis and summaries, or collect them repeatedly or in bulk for storage, ingestion or database creation. Repurposing, redistribution, sale and use to build other services are also prohibited.

Unauthorized use may result in access restrictions, demands to stop infringement and delete copies, and claims for damages. Violations of applicable law may also give rise to criminal liability.

Uses permitted by law, the Terms of Service or a separate agreement remain subject to their respective scope. Rights in individual source materials, including original filings, remain with their respective rights holders.